EU marketing authorization for ViiV Healthcare HIV drug Triumeq

3 September 2014

The European Commission has granted marketing authorization for ViiV Healthcare’s Triumeq(dolutegravir 50mg/abacavir 600mg/lamivudine 300mg) tablets for the treatment of HIV in adults and adolescents aged 12 years and older.

Triumeq is ViiV Healthcare’s first once-daily single-pill dolutegravir-based regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine. Just last month, the drug was approved by the US Food and Drug Administration (The Pharma Letter August 23).

Viiv is a joint venture set up in 2009 that has UK pharma major GlaxoSmithKline (LSE: GSK) as the major partner (76.5%) with US drugs giant Pfizer (NYSE: PFE), with both transferring their AIDS assets into the new company. Japan’s Shionogi (TYO: 4507) joined in 2013 as a minority stakeholder (10%).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK